Acute respiratory distress syndrome

ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target

Retrieved on: 
Tuesday, June 13, 2023
GMP, ASC, University, Diabetes, Leonard M. Miller School of Medicine, The Michael J. Fox Foundation, Cancer, World Health Organization, Research, Inflammation, Cell, Multiple sclerosis, Inflammasome, Patient, Respiratory failure, Traumatic brain injury, Soft tissue injury, Mouse, Acute respiratory distress syndrome, Health, Therapy, Death, Safety, IND, Medicine, Injury, Pharmaceutical industry, DRS

Data suggest that drugs targeting ASC may provide the best opportunity to control damaging inflammation associated with diseases affecting millions of people worldwide.

Key Points: 
  • Data suggest that drugs targeting ASC may provide the best opportunity to control damaging inflammation associated with diseases affecting millions of people worldwide.
  • The white paper titled, “Inflammasome ASC: A Promising Therapeutic Target,” can be accessed by Clicking Here .
  • Fox Foundation.”
    “ZyVersa, which obtained a worldwide license for Inflammasome ASC Inhibitor IC 100, is honored to collaborate with Drs.
  • We are excited about our progress, as we believe Inflammasome ASC Inhibitor IC 100 has potential to transform treatment of debilitating inflammatory diseases.”

Global Acute Respiratory Distress Syndrome Market Report 2023-2028: Industry Trends, Growth, Impact of Inflation, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 7, 2023
Pharmaceutical, Health, Medical Devices, Research and development, Failure, Bed, Hospital, COVID-19, Ageing, Risk, Lung, Government, Incidence, Chronic Respiratory Disease, Patient, Transfusion-related acute lung injury, Developed country, Viral, Acute respiratory distress syndrome, ICU, R, Air pollution, Diagnosis, White lung, Dietary supplement, Pharmaceutical industry, Medical device, Nursing, Growth

The "Acute Respiratory Distress Syndrome Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Respiratory Distress Syndrome Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The other factors forecasted to propel the development of the worldwide acute respiratory distress syndrome (ARDS) market include the rising rate of air pollution and lifestyle-related diseases and Increasing accident rates and trauma-causing ARDS market.
  • However, the high cost of devices, lack of awareness about diseases, failure of trials for ARDS, and stringent regulation for approvals are the main factors restraining the global acute respiratory distress syndrome market.
  • In addition, nebulization devices dominate the acute respiratory distress syndrome market due to their low cost and wide availability.

StemInov Will Bioproduct the First Cell Therapy Drug to Treat Inflammatory Diseases

Retrieved on: 
Monday, June 5, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Clinical Trials, Infection, French Government of the Hundred Days, Umbilical cord, Inflammation, Tech, Septic shock, Stem cell, Trial of the century, Intensive care medicine, Patient, Acute respiratory distress syndrome, B cell, Death, Pharmaceutical industry

StemInov, a biotechnology company developing an innovative biomedicine based on stem cells from umbilical cords to treat inflammatory diseases, septic shock and acute respiratory distress syndrome (ARDS), will bioproduct the first cell therapy drug from umbilical cord stem.

Key Points: 
  • StemInov, a biotechnology company developing an innovative biomedicine based on stem cells from umbilical cords to treat inflammatory diseases, septic shock and acute respiratory distress syndrome (ARDS), will bioproduct the first cell therapy drug from umbilical cord stem.
  • WhartSep, the drug bioproduced by a specific process developed by StemInov, is made of mesenchymal stem cells derived from the umbilical cord (Wharton Jelly WJ-MSC), which have very interesting properties for the treatment of inflammatory diseases.
  • Once manufactured, the biomedicine is frozen in vials that are directly injectable after thawing to patients in intensive care.
  • on June 7th at 2 pm" said Julie Hutin, CEO of StemInov.

Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension

Retrieved on: 
Thursday, June 1, 2023
Molecular biology, Duke University, BS, University, Senior, Allergy, PAH, Biotechnology, Programming Development Manager, WPP, Strategic planning, Doctor of Philosophy, Bachelor of Science, II, Pain, Inflammation, Syneos Health, MD, Patient, Internal medicine, Fatty liver disease, Biology, Acute respiratory distress syndrome, Hospital, Newcastle University, Pulmonary hypertension, Orthostatic hypertension, ChromeOS, Pharmacology, Conatus, Pfizer, Management, Pharmaceutical industry, New York University

Joshua Ziel, PhD was appointed as Chief Operating Officer and will act as Chief Executive Officer as the company advances AER-901 into Phase 2.

Key Points: 
  • Joshua Ziel, PhD was appointed as Chief Operating Officer and will act as Chief Executive Officer as the company advances AER-901 into Phase 2.
  • Additionally, the company has appointed Gary Burgess, MD, as Chief Medical Officer, and Sarah Fritchley, PhD, as Senior Vice President, Clinical Development and Operations.
  • He joined Aerami in 2022 as Vice President for Program Development with oversight on strategy and execution for the AER-901 pulmonary hypertension program.
  • Dr. Fritchley received her BSc degree in pharmacology from the University of Sheffield, followed by a PhD in immunology from Newcastle University.

Revolo Biotherapeutics Presents New Preclinical Data for ‘1104 in Acute Respiratory Distress Syndrome Associated With Influenza Infection at the ATS 2023 International Conference

Retrieved on: 
Monday, May 22, 2023
IAV, Infection, Mouse, MOA, Eosinophilic esophagitis, TNF, Neutrophil, Allergy, Macrophage, Gastric lavage, ATS, Influenza A virus, IL-6, Inflammation, American Thoracic Society, Lung, Dexamethasone, Animal, International Conference on Emerging Infectious Diseases, Organic acid, Patient, Immune system, Viral, Viral load, Acute respiratory distress syndrome, Chemokine, Cytokine, Lymphocyte, Immunosuppression, Conference, PBS, Autoimmunity, Disease, Vaccine, Revolo

NEW ORLEANS and CAMBRIDGE, UK,, May 22, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced new preclinical data discussed in a poster presentation at the American Thoracic Society (ATS) 2023 International Conference. The poster showcases the ability of its immune-resetting drug candidate ‘1104 to inhibit and reduce lung inflammation without immunosuppression in a new model of acute respiratory distress syndrome (ARDS) associated with influenza infection.

Key Points: 
  • The poster showcases the ability of its immune-resetting drug candidate ‘1104 to inhibit and reduce lung inflammation without immunosuppression in a new model of acute respiratory distress syndrome (ARDS) associated with influenza infection.
  • “The data continues to highlight the unique mechanism of action (MOA) of ‘1104, acting ahead of the inflammatory cascade to reset the immune system.
  • Three days after infection, animals received either PBS (negative control) or 30µg of polyinosinic-polycytidylic acid (poly I:C) to exacerbate influenza-induced lung inflammation.
  • At 48 hours after the poly I:C challenge, bronchoalveolar lavage fluid was collected to conduct differential cell counts and to measure cytokines.

SeaStar Medical Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Monday, May 15, 2023
Insurance, Hospice and palliative medicine, Neutrophil, Chronic kidney disease, Marketing, HDE, SCD, Clinical trial, G&A, AKI, Dialysis, Sepsis, Acute kidney injury, CKRT, Hospital, Monocyte, Patient, Standard of care, Nephrology, Risk, Physician, HIV disease progression rates, Clinical study design, Acute respiratory distress syndrome, Mortality, ICU, R, FDA, Letter, Research, Safety, Pharmaceutical industry, Nursing, Security (finance)

DENVER, May 15, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three months ended March 31, 2023 and provides a business update.

Key Points: 
  • DENVER, May 15, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three months ended March 31, 2023 and provides a business update.
  • Approximately six million cases of adult AKI are diagnosed annually in the U.S., of which approximately 200,000 require CKRT.
  • The NEUTRALIZE-AKI trial is expected to enroll up to 200 patients at up to 30 U.S. medical centers.
  • Other expense for the first quarter of 2023 was $0.5 million, compared with other expense of $0.2 million for the first quarter of 2022.

Global Biomarkers Markets, 2017-2021 & 2022-2028: A Highly Competitive Market with 800+ Players - Niche Players Control About ~77% of the Market - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 9, 2023
Health, Other Health, Prevalence, IVDD, Abbott Laboratories, Prognosis, Key, Privacy, Bangladesh Technical Education Board, App Store (iOS/iPadOS), Plasma, COVID-19, Thermo Fisher Scientific, Patient, Investment, Merck, Database, General Electric, Therapy, Heart failure, Disease, NGS, SARS-CoV-2, Risk, USD, Biomarker, Medicine, Diagnosis, Growth, Acute respiratory distress syndrome, Death, BD, DNA, FNIH, Roche, Qiagen, Algorithm, Johnson & Johnson, Epigenomics AG, DHT, Bristol Myers Squibb, RNA, Novartis, PerkinElmer, Artificial intelligence, AI, FTD, Pfizer, Video game, Generic drug, Vaccine, Medical device, Pharmaceutical industry, Fine chemical, Oil, Neurodegenerative disease

The growing popularity of remote technologies such as wearables and mobile applications is fuelling the digital biomarker market (DBMs) growth.

Key Points: 
  • The growing popularity of remote technologies such as wearables and mobile applications is fuelling the digital biomarker market (DBMs) growth.
  • Country-Niche players control about ~77% of the market, while regional players hold a share of ~18%.
  • Though the market is highly competitive with over ~800 participants, few country-niche players control the dominant share.
  • The Global Biomarkers Market is covered from 2017-2028 in this report, which includes a forecast for the period 2022-2028
    What is the Future Growth Rate of the Global Biomarkers Market?

Global Home Health Market Report 2022: Introduction of AI, Big Data, and Automation Present New Avenues for Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 5, 2023
Managed Care, Health, Well, COPD, Diabetes, CPAP, Hospital, Arthritis, Coronavirus, COVID-19, Cancer, Service, WISH, Element, USD, Government, Chronic obstructive pulmonary disease, Patient, Automation, Nebulizer, Plant growth analysis, Acute respiratory distress syndrome, Diagnosis, AI, Continuous positive airway pressure, Video game, Health insurance, Nursing

The "Global Home Health Market Size, Share, Growth Analysis, By Product, By Service - Industry Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Home Health Market Size, Share, Growth Analysis, By Product, By Service - Industry Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • Old people demand more patient-centric healthcare services, which increases the demand for healthcare workers and agencies, this is expected to drive the market growth.
  • This report provides in-depth analysis of Global Home Health market.
  • The market for home health care will provide more than just health care because of the pandemic.

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

Retrieved on: 
Thursday, May 4, 2023
EUA, Vaccine, SARS-CoV-2, COVID-19, NDA, Trial of the century, Fast track (FDA), Death, Patient, Comorbidity, Acute respiratory distress syndrome, Mortality, ICU, FDA, Respiratory failure, Safety, Breast cancer, Pharmaceutical industry, Arcturus

Based on the FDA's positive feedback on the confirmatory Phase 3 clinical study design and program, the Company anticipates initiating the clinical study in the second half of 2023.

Key Points: 
  • Based on the FDA's positive feedback on the confirmatory Phase 3 clinical study design and program, the Company anticipates initiating the clinical study in the second half of 2023.
  • As the program has FDA Fast Track designation, a rolling NDA submission is a possibility for sabizabulin.
  • “We look forward to expanding the clinical development of sabizabulin into a broader group of hospitalized patients at high risk for ARDS.
  • We believe sabizabulin could emerge as the leading treatment option for hospitalized patients at high risk for viral associated ARDS broadly."

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, May 4, 2023
MYC, Therapy, Hepatocellular carcinoma, OEC, Drug discovery, Roche, Pharmacokinetics, Omega, G&A, NSCLC, COVID, Part, Lung cancer, Immunotherapy, Messenger, Annual general meeting, ASCO, Gastrointestinal tract, Patient, TME, Acute respiratory distress syndrome, Growth, CDT, R, Research, Security, Society, IND, HCC, Safety, Pharmaceutical industry, Cryptocurrency

“During the first quarter we made progress across our clinical and preclinical programs in line with our broader strategic vision,” said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics.

Key Points: 
  • “During the first quarter we made progress across our clinical and preclinical programs in line with our broader strategic vision,” said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics.
  • Research and development (R&D) expenses for the first quarter of 2023 were $20.0 million, compared to $14.2 million for the first quarter of 2022.
  • General and administrative expenses (G&A) for the first quarter of 2023 were $6.0 million, compared with $5.4 million for the first quarter of 2022.
  • Net loss for the first quarter of 2023 was $25.3 million, compared with $20.2 million for the first quarter of 2022.